Antimicrobial therapy using a local drug delivery system (Arestin®) in the treatment of peri-implantitis. I: microbiological outcomes

    loading  Checking for direct PDF access through Ovid



To assess the microbiological outcome of local administration of minocycline hydrochloride microspheres 1 mg (Arestin®) in cases with peri-implantitis and with a follow-up period of 12 months.

Material and methods

After debridement, and local administration of chlorhexidine gel, peri-implantitis cases were treated with local administration of minocycline microspheres (Arestin®). The DNA–DNA checkerboard hybridization method was used to detect bacterial presence during the first 360 days of therapy.


At Day 10, lower bacterial loads for 6/40 individual bacteria including Actinomyces gerensceriae (P<0.1), Actinomyces israelii (P<0.01), Actinomyces naeslundi type 1 (P<0.01) and type 2 (P<0.03), Actinomyces odontolyticus (P<0.01), Porphyromonas gingivalis (P<0.01) and Treponema socranskii (P<0.01) were found. At Day 360 only the levels of Actinobacillus actinomycetemcomitans were lower than at baseline (mean difference: 1 × 105; SE difference: 0.34 × 105, 95% CI: 0.2 × 105 to 1.2 × 105; P<0.03). Six implants were lost between Days 90 and 270. The microbiota was successfully controlled in 48%, and with definitive failures (implant loss and major increase in bacterial levels) in 32% of subjects.


At study endpoint, the impact of Arestin® on A. actinomycetemcomitans was greater than the impact on other pathogens. Up to Day 180 reductions in levels of Tannerella forsythia, P. gingivalis, and Treponema denticola were also found. Failures in treatment could not be associated with the presence of specific pathogens or by the total bacterial load at baseline. Statistical power analysis suggested that a case control study would require approximately 200 subjects.

Related Topics

    loading  Loading Related Articles